Cornerstone Capital Group will participate in this event.
Our 4th annual Roundtable for biopharma sustainability leaders will gather to discuss industry-specific challenges and opportunities, and to continue building an active network of colleagues.
Day 1 & 2 – April 13-14 – Roundtable sessions at Novartis Institutes for Biomedical Research (NIBR), Cambridge, MA
Day 3 – April 15 – “Investor Perspective Workshop” at Cornerstone Capital Group in New York
A one-day interactive discussion and networking opportunity for senior biopharma Finance, Risk, and Sustainability officers to talk directly with financial market actors – analysts, portfolio managers, and asset managers – about sustainability performance and market value.
Our workshop in Manhattan will again connect biopharma leaders who have responsibility for sustainability strategy and reporting, with the investors, financial analysts, and asset managers who use the data to guide investment decisions. Gbola Amusa, Dir. of Research at Chardan Capital Markets, will address sustainability and valuation. Philipp Abey, CEO and co-founder of RepRisk, will lead off the Biopharma Perspectives panel, and SASB’s new Healthcare Sector Lead will join us to share early adopter experience and potential updates to the reporting standard, and Olga Emelianova, VP for ESG Research at MSCI, will moderate a panel on the value and uses of sustainability/ESG performance information. John Wilson, Head of Governance, Engagement, & Research at Cornerstone Capital Group, will have the last word on how a focus on materiality, metrics and transparency is key to driving sustainability performance in our industry.
For more details, visit the event registration page.